bosentan anhydrous has been researched along with Cardiac Septal Defect in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, F; Ren, R; Xiao, X | 1 |
| Schulze-Neick, I | 1 |
2 other study(ies) available for bosentan anhydrous and Cardiac Septal Defect
| Article | Year |
|---|---|
Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Mitral Valve Insufficiency; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
[PAH in congenital heart defects--therapeutic experiences with children and adults].
Topics: Antihypertensive Agents; Bosentan; Child; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Defects, Congenital; Heart Septal Defects; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome; Vascular Resistance | 2005 |